IWAA 2022 Annual Meeting
The 2022 annual meeting of the Intermountain West Allergy Association (IWAA) will take place in Coeur d'Alene, Idaho on August 11-13 and be attended by 60 clinicians, including allergists-immunologists, fellows in accredited allergy/immunology training programs, allied health professionals, and primary care physicians who care for allergy patients. The purpose of IWAA’s annual meeting is to improve patient outcomes by increasing attendees’ knowledge of the latest research, guidelines, and expert opinion relevant to the diagnosis and management of patients with allergy, asthma, and immunological disorders. This year, the IWAA annual meeting’s theme is "An Allergy Science Potpourri." It will include two full days of sessions led by nationally recognized experts on topics such as food allergy treatment, severe asthma management, adult vaccination schedules, long COVID-19, chronic spontaneous Urticaria, understanding the immunology of HIV and eosinophilic gastrointestinal disorders. In addition, there will be a Practice Management Symposium. The small, intimate meeting atmosphere allows ample opportunity for knowledge sharing and collaboration among attendees and presenters..
Accreditation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of American College of Allergy, Asthma & Immunology and Intermountain West Allergy Association. The American College of Allergy, Asthma & Immunology is accredited by the ACCME to provide continuing medical education for physicians.
Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 15 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Target Audience
Practicing allergists
Allied health professionals
Learning Objectives
Upon completion of this activity the participant should be able to:
1. Summarize recent data, expert opinion and clinical practice guidelines on the treatment of allergic and immunological disease.
2 Describe the safety and efficacy profiles of established and emerging therapies for the treatment of allergic and immunological diseases.
3. Apply knowledge of the pathophysiology of allergic and immunological diseases to clinical decision-making.
All identified conflicts of interest have been mitigated.
The individuals listed below disclose the following financial relationships:
Doug Huneywell | Planner | No Relevant Financial Relationships with ineligible companies to disclose. |
Ron England, M.D. | Board of Director | No Relevant Financial Relationships with ineligible companies to disclose |
Richard Henry, M.D. | Board of Director | No Relevant Financial Relationships with ineligible companies to disclose |
Carl Thornblade, M.D. | Board of Director | Regeneron, Ind. Contractor Dermavant Sciences – Ind. Contractor Novartis – Ind. Contractor Verona – Ind. Contractor Satsuma – Ind. Contractor TEVA – Ind. Contractor Genentech – Ind. Contractor Shionugi – Ind. Contractor Bellus Health – Ind. Contractor Galderma – Ind. Contractor Bayer – Ind. Contractor |
Greg Wickern, M.D. | Board of Director | No Relevant Financial Relationships with ineligible companies to disclose |
Allen Kaplan, M.D. | Speaker | BioCryst – Advisor, Speaker Genentech – Advisor Pharming – Advisor, Speaker Abb-RISA – Advisor Takeda – Advisor, Speaker |
Samuel Louie, M.D. | Speaker | AstraZeneca – Advisor, Speaker Boehringer Ingelheim – Advisor, Speaker Genentech – Advisor, Speaker GSK - Advisor, Speaker Regeneron – Advisor, Speaker Sanofi Genzyme – Advisor, Speaker Amgen - Speaker |
Bryan Martin, D.O. | Speaker | ALK - Advisor |
Michael Peluso, M.D. | Speaker | No Relevant Financial Relationships with ineligible companies to disclose |
James Thompson, PhD | Speaker | No Relevant Financial Relationships with ineligible companies to disclose |
Amiko Uchida, M.D. | Speaker | Sanofi-Regeneron – Advisor Takeda - Researche |
Available Credit
- 15.00 AMA PRA Category 1 Credit™
- 15.00 Attendance